Published in Protein Sci on July 20, 2017
Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J Mol Biol (2003) 8.35
FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol (2007) 7.94
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
Role of conformational sampling in computing mutation-induced changes in protein structure and stability. Proteins (2010) 2.56
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng (1996) 2.44
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res (2008) 2.33
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell (2008) 2.21
Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol (1997) 2.13
Alternate states of proteins revealed by detailed energy landscape mapping. J Mol Biol (2010) 1.90
Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol (2005) 1.90
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs (2010) 1.89
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol (2014) 1.77
Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol (2015) 1.76
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem (2010) 1.60
Scientific benchmarks for guiding macromolecular energy function improvement. Methods Enzymol (2013) 1.59
Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure (2016) 1.45
Bispecific antibodies. Drug Discov Today (2015) 1.44
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A (2013) 1.42
Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel (2008) 1.34
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs (2009) 1.30
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol (2012) 1.30
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs (2012) 1.29
Combined covalent-electrostatic model of hydrogen bonding improves structure prediction with Rosetta. J Chem Theory Comput (2015) 1.15
A generic program for multistate protein design. PLoS One (2011) 1.03
Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs (2015) 1.02
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs (2013) 0.98
Anchored design of protein-protein interfaces. PLoS One (2011) 0.96
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem (2015) 0.95
Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins (2009) 0.94
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun (2015) 0.93
Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem (2009) 0.91
Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem (2006) 0.91
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor. Cancer Chemother Pharmacol (2015) 0.90
Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. J Mol Biol (2014) 0.88
Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-α receptor 1. J Clin Immunol (2013) 0.86
Targeting T cells with bispecific antibodies for cancer therapy. BioDrugs (2011) 0.85
The making of bispecific antibodies. MAbs (2017) 0.84
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection. Curr Opin Immunol (2016) 0.81
Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs (2015) 0.81
Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins. Front Immunol (2016) 0.80
Despite slow progress, bispecifics generate buzz. Nat Biotechnol (2016) 0.77
Enhanced plasmid DNA utilization in transiently transfected CHO-DG44 cells in the presence of polar solvents. Biotechnol Prog (2015) 0.77
Transcriptional and post-transcriptional targeting for enhanced transient gene expression in CHO cells. Biotechnol Lett (2015) 0.76
A high cell density transient transfection system for therapeutic protein expression based on a CHO GS-knockout cell line: process development and product quality assessment. Biotechnol Bioeng (2015) 0.76
Transient and Stable CHO Expression, Purification and Characterization of Novel Hetero-dimeric Bispecific IgG Antibodies. Biotechnol Prog (2016) 0.76
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. MAbs (2016) 0.75
Comparing domain interactions within antibody Fabs with kappa and lambda light chains. MAbs (2016) 0.75
Enhanced tumor-targeting selectivity by modulating bispecific antibody binding affinity and format valence. Sci Rep (2017) 0.75